MedPath

拜耳医药保健有限公司

Ownership
-
Established
1995-08-25
Employees
-
Market Cap
-
Website
https://www.bayer.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

19

NMPA:19

Drug Approvals

Rivaroxaban tablets

Product Name
利伐沙班片
Approval Number
国药准字H20253671
Approval Date
Mar 18, 2025
NMPA

Rivaroxaban tablets

Product Name
利伐沙班片
Approval Number
国药准字H20253670
Approval Date
Mar 18, 2025
NMPA

Rivaroxaban tablets

Product Name
利伐沙班片
Approval Number
国药准字H20253672
Approval Date
Mar 18, 2025
NMPA

Rivaroxaban tablets

Product Name
利伐沙班片
Approval Number
国药准字H20253669
Approval Date
Mar 18, 2025
NMPA

Acarbose Tablets

Product Name
拜唐苹
Approval Number
国药准字H19990205
Approval Date
Nov 5, 2024
NMPA

Acarbose Tablets

Product Name
拜唐苹
Approval Number
国药准字H20010716
Approval Date
Oct 22, 2024
NMPA

Nimodipine Tablets

Product Name
尼膜同
Approval Number
国药准字H20003010
Approval Date
Oct 18, 2024
NMPA

Hydrotalcite Chewable Tablets

Product Name
达喜
Approval Number
国药准字H20013410
Approval Date
May 16, 2024
NMPA

Etofenamate Cream

Product Name
优迈
Approval Number
国药准字H20020117
Approval Date
Jan 28, 2021
NMPA

Etofenamate Cream

Product Name
优迈
Approval Number
国药准字H20020118
Approval Date
Jan 25, 2021
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.